tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SeaStar Medical Announces Share Offering to Raise Funds

Story Highlights
  • SeaStar Medical announced a public offering to raise $3.39 million for corporate purposes.
  • The company implemented cost-cutting measures, reducing executive and director salaries by 20%.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
SeaStar Medical Announces Share Offering to Raise Funds

Elevate Your Investing Strategy:

SeaStar Medical Holding ( (ICU) ) has shared an announcement.

On June 20, 2025, SeaStar Medical Holding Corporation announced a public offering of shares and warrants, expected to raise approximately $3.39 million in net proceeds, which will be used for general corporate purposes. The offering closed on June 23, 2025, and is part of the company’s efforts to comply with Nasdaq’s listing requirements. Additionally, SeaStar Medical implemented cost-cutting measures, including a 20% salary reduction for executives and directors, to reduce monthly operating expenses by approximately $50,000.

The most recent analyst rating on (ICU) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on SeaStar Medical Holding stock, see the ICU Stock Forecast page.

Spark’s Take on ICU Stock

According to Spark, TipRanks’ AI Analyst, ICU is a Underperform.

SeaStar Medical Holding faces significant financial challenges, with negative equity and reliance on external financing posing risks to its financial health. Technical indicators show bearish momentum, and valuation metrics highlight ongoing losses, contributing to a low overall stock score.

To see Spark’s full report on ICU stock, click here.

More about SeaStar Medical Holding

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The company’s first commercial product, QUELIMMUNE, was approved by the FDA in 2024 for treating life-threatening acute kidney injury due to sepsis in critically ill pediatric patients. SeaStar is also conducting a pivotal trial of its Selective Cytopheretic Device therapy for adult patients with acute kidney injury.

Average Trading Volume: 527,156

Technical Sentiment Signal: Sell

Current Market Cap: $3.95M

For detailed information about ICU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1